Characterisation and validation of a murine model of global ischaemia-reperfusion injury

Author(s):  
Mark S. Sumeray ◽  
Derek M. Yellon
2008 ◽  
Vol 21 (7) ◽  
pp. 688-695 ◽  
Author(s):  
Nele Geudens ◽  
Lien Timmermans ◽  
Hadewijch Vanhooren ◽  
Bart M. Vanaudenaerde ◽  
Robin Vos ◽  
...  

2020 ◽  
Vol 10 (3) ◽  
pp. 228-235 ◽  
Author(s):  
Ernest Cheung ◽  
Mehrdad Nikfarjam ◽  
Louise Jackett ◽  
Damien M. Bolton ◽  
Joseph Ischia ◽  
...  

Heart ◽  
2017 ◽  
Vol 103 (Suppl 5) ◽  
pp. A138.3-A139
Author(s):  
John Mulvey ◽  
Angela Logan ◽  
Sabine Arndt ◽  
Victoria Pell ◽  
Stuart Caldwell ◽  
...  

2018 ◽  
Vol 24 (23) ◽  
pp. 2692-2700 ◽  
Author(s):  
H. Susana Marinho ◽  
Paulo Marcelino ◽  
Helena Soares ◽  
Maria Luísa Corvo

Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach. Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation. Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs. Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects. Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.


Sign in / Sign up

Export Citation Format

Share Document